Request Demo
Fibrotic diseases company Certa acquires OccuRx
18 Dec 2024
AcquisitionPhase 1Phase 2
Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx.
Certa says that OccuRx has highly complementary assets, resources and expertise, and a shared focus on targeting GPR68, a master switch of fibrosis.
The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Darren Kelly, consolidating a pipeline that now includes two Phase II and one Phase I clinical candidates.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
WCLC 2026 Plenary Studies Clinical Evidence Review Report
Patsnap Synapse
ESC Congress 2026 Clinical Evidence Review: Seven Pivotal Trials, Guideline Updates, and AI Findings
Patsnap Synapse
Oligonucleotide Therapeutics Report: What Patent Intelligence Reveals About the Next Wave of Platform Competition
Patsnap Synapse
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!